Discussion on the clinical application effect of F/TAF blocking drugs and whether they are worthy of long-term use

F/TAF is a new type of antiviral blocking drug, mainly used as an auxiliary program for HIV prevention (PrEP) and treatment, and has attracted widespread attention around the world. Its drug ingredient is tenofovir alafenamide fumarate (F/TAF), which blocks the extension of the viral replication chain by inhibiting HIV reverse transcriptase activity. In recent years, multiple clinical studies have shown that F/TAF has shown high efficacy in blocking HIV infection, and has significantly improved safety and tolerability compared with older generation drugs.

In terms of clinical application, F/TAF is mainly used for pre-exposure prophylaxis (PrEP) in high-risk groups. Large multi-center clinical trials have shown that daily oral administration of F/TAF can significantly reduce the risk of HIV infection and is more effective than traditional TDF/FTC combination drugs. Research data shows that after patients with good compliance receive F/TAF blocking treatment, the HIV infection rate can be reduced to nearly zero levels, demonstrating its powerful advantages in preventing infection. In addition, for patients already infected with HIV, F/TAF can also be used as part of antiviral combination therapy to improve the viral suppression rate and delay the development of drug resistance.

Regarding the question of whether it is worth taking long-term use, F/TAF is safer than TDF in long-term use. F/TAF has less impact on renal function and bone density, making it safer for high-risk groups to use for long-term prevention. However, long-term medication still requires attention to potential side effects, including mild gastrointestinal discomfort, headache, and occasional fluctuations in renal function indicators. Therefore, clinically, it is generally recommended that patients regularly review blood routine, liver and kidney function, and HIV virological indicators under the guidance of a doctor to ensure the safe use and efficacy monitoring of the drug.
In addition, when patients consider long-term use of F/TAF, they should also comprehensively evaluate their own infection risks, financial burden, lifestyle habits and other factors. Patients with frequent high-risk behaviors and greater exposure risks can first choose to take long-term blocking drugs, while low-risk groups can consider short-term medication as needed or combined with other preventive methods. Overall, F/TAF has become the current drug of choice for PrEP protection due to its excellent efficacy, low adverse reactions and improvement in bone and kidney toxicity. However, long-term use still needs to be carried out under the guidance of professional medical personnel, with regular follow-up and evaluation of efficacy and safety, in order to maximize its preventive value and reduce potential risks.
Reference: https://www.drugs.com/